SCHEMBL2138149

SCHEMBL2138149

Fc1ccccc1-c1nc2ccccc2s1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.66
NPC1 O15118 9/20 0.66
RAB9A P51151 9/20 0.66
ALDH1A1 P00352 7/20 0.66
MAPT P10636 6/20 0.66
SMN1; SMN2 Q16637 5/20 0.66
MEN1 O00255 4/20 0.66
KMT2A Q03164 4/20 0.66
GAA P10253 4/20 0.66
L3MBTL1 Q9Y468 4/20 0.66
TDP1 Q9NUW8 2/20 0.66
NPSR1 Q6W5P4 2/20 0.56
POLB P06746 2/20 0.54
HSD17B10 Q99714 3/20 0.53
TP53 P04637 2/20 0.53
TSHR P16473 1/20 0.53
ILK Q13418 2/20 0.53
GLA P06280 2/20 0.53
HCRTR1 O43613 1/20 0.53
APP P05067 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL231307 0.88 KDM4E (0.75) KDM4ENPC1RAB9AALDH1A1MAPT
SCHEMBL28510736 0.87 NPC1 (0.64) KDM4ENPC1RAB9AALDH1A1MAPT
SCHEMBL29657261 0.87 NPC1 (0.64) KDM4ENPC1RAB9AALDH1A1MAPT
SCHEMBL12854008 0.86 KDM4E (0.72) KDM4ENPC1RAB9AALDH1A1MAPT
SCHEMBL17180047 0.83 KDM4E (0.57) KDM4ENPC1RAB9AALDH1A1MAPT
SCHEMBL4593570 0.82 KDM4E (0.65) KDM4ENPC1RAB9AALDH1A1MAPT
SCHEMBL11645498 0.81 NPC1 (0.47) KDM4ENPC1RAB9AALDH1A1MAPT
SCHEMBL827403 0.81 RAB9A (0.67) KDM4ENPC1RAB9AALDH1A1MAPT
SCHEMBL29528497 0.80 NPC1 (0.56) KDM4ENPC1RAB9AALDH1A1MAPT
SCHEMBL19149022 0.80 MAPT (0.59) KDM4ENPC1RAB9AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101368094-A Yellow electrophosphorescent iridium complex, preparation method and uses thereof CHANGCHUN OPTICS FINE MECH (CN) 2009-02-18 CN claimed
EP-0721336-B1 BENZAZOLE COMPOUNDS FOR USE IN THERAPY CANCER RES CAMPAIGN TECH (GB) 1999-07-14 EP claimed
EP-0721336-A1 BENZAZOLE COMPOUNDS FOR USE IN THERAPY CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) 1996-07-17 EP claimed
WO-1995006469-A1 BENZAZOLE COMPOUNDS FOR USE IN THERAPY CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) 1995-03-09 WO claimed
US-11384060-B2 Amide compounds and use thereof ALPHALA CO., LTD. (TW) 2022-07-12 US disclosed
US-20190337915-A1 AMIDE COMPOUNDS AND USE THEREOF ALPHALA CO., LTD. (TW) 2019-11-07 US disclosed
CN-109338402-A A kind of method of electro-catalysis benzo thioamide analog compound synthesis benzothiazole in water 福建医科大学 2019-02-15 CN disclosed
CN-109293599-A A kind of method of microwave radiation benzo thioamide analog compound synthesis benzothiazole in water phase 福建医科大学 2019-02-01 CN disclosed
CN-106432132-A Preparation method of 2-arylbenzothiazole compound 西北师范大学 2017-02-22 CN disclosed
CN-105777662-A Benzoxazole and benzimidazole compounds and preparation method thereof 信阳师范学院 2016-07-20 CN disclosed
CN-103951635-B A kind of synthetic method being used as the thiazole compound of Neurology Department pharmaceutical intermediate ZHONGXIN HOSPITAL, QINGDAO (CN) 2015-11-25 CN disclosed
CN-103788013-B Synthetic method of 2-aryl benzothiazole compounds UNIV WENZHOU 2015-07-01 CN disclosed
CN-1642879-A Process for preparing diaryl compounds SUMITOMO CHEMICAL CO (JP) 2005-07-20 CN disclosed
US-20050096471-A1 Process for producing biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-05-05 US disclosed
EP-1487843-A2 SUBSTITUTED PHENYLACETIC ACIDS Metabolex, Inc. (US) 2004-12-22 EP disclosed
EP-1473286-A1 PROCESS FOR PRODUCING BIARYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2004-11-03 EP disclosed
US-20040029933-A1 Substituted phenylacetic acids METABOLEX, INC. 2004-02-12 US disclosed
WO-2003080545-A2 SUBSTITUTED PHENYLACETIC ACIDS METABOLEX, INC. (US) 2003-10-02 WO disclosed
EP-0721336-B1 BENZAZOLE COMPOUNDS FOR USE IN THERAPY CANCER RES CAMPAIGN TECH (GB) 1999-07-14 EP disclosed
US-5874431-A ANTITUMOR AGENTS; BREAST CANCER CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) 1999-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190337915-A1 AMIDE COMPOUNDS AND USE THEREOF GLP1R, IAPP, GPR119 KDM4E 2631/4885NPC1 1116/4885RAB9A 1229/4885
US-20040029933-A1 Substituted phenylacetic acids PNLIP, PC, PAOX KDM4E 3805/4885NPC1 305/4885RAB9A 2953/4885
US-20050096471-A1 Process for producing biaryl compound PPOX, CAT, TYR KDM4E 3428/4885NPC1 4102/4885RAB9A 2254/4885
US-11384060-B2 Amide compounds and use thereof GLP1R, IAPP, GPR119 KDM4E 2631/4885NPC1 1116/4885RAB9A 1229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.